Who We are


  • acquisition of Soneas, a CDMO based out of Budapest, Hungary.


  • Personal Care Divesture to Clariant


  • Focused on integration and simulation
  • Acquisition of APMPL, a US FDA approved FDF facility has opened doors in the regulated markets for generics
  • Recent PIC/S GMP approval; access to the regulated CIS market for formulations
  • All building blocks in place to take healthcare segment to the next level of growth


  • Investment for future pipeline
  • Commissioning of Bidar block for Pharma Intermediates
  • Upgradation of Jeedimetla facility to PICS standards
  • Established API R&D with 65 scientists and formulations R&D with 45 scientists
  • Health Canada approval for FR&D centre


  • Harnessing the future
  • Focused on strengthening the API business with backward integration and procurement synergies


  • Embarked upon building an integrated Healthcare company vis-à-vis pure play Spechem player
  • Acquired Uquifa which marked Vivimed’s entry into the API domain; added new customers, diversified product portfolio and 3 USFDA approved manufacturing facilities.
  • Acquired Klar Sehen and Octantis Nobel to establish footprint in the domestic FDF market as branded manufacturer


  • Expansion of Product Portfolio & Clientele
  • Listed on BSE & NSE
  • Development of new active ingredients
  • Introduction of Small Volume Parentals facility and Specialty Chemicals facility
  • Added new customers such as L’Oreal, P&G
  • Inorganic Growth Healthcare
  • Acquired Uquifa, Octtantis Nobel, Klar Sehen, Finoso and Actavis SOD facility to increase presence in API’s & formulations
  • Active Ingredients: Acquired James Robinson to increase global presence and increase product portfolio


  • Breakthrough in Specialty Chemicals
  • Established R&D center Approved by Unilever for the supply of Viv-20 and Vivcal-G to Unilever’s Asian locations


  • Exploration into Specialty Chemicals- VIV-20 Patent grant by Indian Patents Office
  • Foray into specialty chemicals through development and process innovation of Anti-Bacterial Viv-20 (Triclosan)


  • API and Bulk Drug Manufacturing – Commenced production at Bidar, Karnataka.
  • Manufacturing of API’s and Bulk Drugs such as Ibuprofen, Chlorzoxazone, Nalidixic Acid.


  • Inception as contract manufacturer for Bulk Drug